GSK (GSK) announced that the China National Medical Products Administration, CNMPA, has accepted for review the new drug application for the ...

England’s cost effectiveness body NICE has recommended GSK’s new severe asthma treatment Nucala, reversing an earlier decision to reject it. Nucala (mepolizumab) is the first biologic ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody that targets interleukin-5, as an add-on therapy with intranasal ...

GSK plc has announced that the China National Medical Products Administration has accepted for review the new drug ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

Nucala (mepolizumab) is a brand-name subcutaneous injection that comes in different forms. Depending on which form you’re prescribed, you or your doctor will administer the injection.

China NMPA accepts for review GSK’s Nucala NDA to treat patients with chronic obstructive pulmonary disease: London, UK Friday, February 21, 2025, 09:00 Hrs [IST] GSK plc announ ...

Blue Cross Blue Shield (BCBS), under its parent company Health Care Service Corporation, is changing how certain asthma injections are administered.

The data suggest that Nucala could offer a meaningful benefit to those in need of additional treatments to reduce exacerbation risks. If approved, Nucala would be the first biologic with monthly ...

GSK PLC on Thursday said its monoclonal antibody Nucala, also known as mepolizumab, has been accepted for review in China. The London-based pharmaceutical company said the China Medical Products ...